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ABSTRACT
Somatic hypermethylation of the O6-methylguanine-DNA methyltransferase gene 
(MGMT) was previously associated with G > A transition mutations in KRAS and TP53 
in colorectal cancer (CRC). We tested the association of MGMT methylation with 
G > A mutations in KRAS and TP53 in 261 CRCs. Sixteen cases, with and without 
MGMT hypermethylation, were further analyzed by exome sequencing. No significant 
association of MGMT methylation with G > A mutations in KRAS, TP53 or in the 
whole exome was found (p > 0.5 in all comparisons). The result was validated by in 
silico comparison with 302 CRCs from The Cancer Genome Atlas (TCGA) consortium 
dataset. Transcriptional silencing associated with hypermethylation and stratified 
into monoallelic and biallelic. We also found a significant clustering (p = 0.001) 
of aberrant hypermethylation of MGMT and the matrix metalloproteinase gene 
ADAMTS14 in normal colonic mucosa of CRC patients. This suggested the existence 
of an epigenetic field defect for cancerization disrupting the methylation patterns of 
several loci, including MGMT or ADAMTS14, that may lead to predictive biomarkers 
for CRC. Methylation of these loci in normal mucosa was more frequent in elder 
(p = 0.001) patients, and particularly in African Americans (p = 1 × 10−5), thus 
providing a possible mechanistic link between somatic epigenetic alterations and CRC 
racial disparities in North America.
INTRODUCTION
The etiology of oncogenic mutations in colorectal 
cancer (CRC) is only explainable in cancers with 
microsatellite instability (MSI) [1]. MSI is originated by 
defects in the DNA mismatch repair (MMR) system and 
is the hallmark of the Hereditary Non-Polyposis Colon 
Cancer (HNPCC) syndrome [2, 3]. Germ line mutations 
in MMR genes, combined with other somatic alterations 
in the remaining allele impair MMR and, as a result, 
hundreds of thousands of spontaneous DNA replication 
errors accumulate in the genome in the course of multiple 
consecutive cell replications. MSI is also manifested in 
approximately 10–15% and 15–20% of non-hereditary 
CRC and endometrial cancer (EC) [1–4], predominantly 
as a result of epigenetic silencing of MLH1 linked to 
promoter hypermethylation [5, 6].
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MSI tumors display a mutator phenotype that 
raises the tumor cell mutation rate two to three orders of 
magnitude over that of normal cells [2, 7]. Paradoxically, 
despite their mutator phenotype, the frequency of 
mutations in the prototypical cancer genes for CRC, KRAS 
and TP53, is lower in MSI tumors than in tumors without 
MSI [1]. This can be explained as the MSI mutator 
phenotype leads to biallelic mutations in other oncogenic 
target genes such as TGFRBII and BAX [8, 9].
Activation of ras oncogenes is implicated in 
human carcinogenesis [10], mainly by promoting cellular 
proliferation and inhibiting apoptosis [11]. KRAS mutations 
occur frequently in tumors of the pancreas and the lung, 
and colorectal adenomas and carcinomas [12, 13]. Point 
mutations of KRAS also occur in 10% to 40% of EC [14].
The tumor suppressor gene TP53 is a checkpoint 
regulator that has been named the “guardian of the 
genome” [15]. The frequency of TP53 somatic point 
mutations in CRC is estimated to be above 50%. The 
majority (approximately 80%) are G > A missense 
transition mutations at CpG dinucleotides that mainly occur 
in five hotspot codons (175, 245, 248, 273, and 282) [16].
O6-methylguanine-DNA methyltransferase (MGMT) 
is an ubiquitous DNA repair enzyme that removes mutagenic 
and cytotoxic adducts from the O6-guanine in DNA, the 
preferred point of attack by many carcinogens and alkylating 
chemotherapeutic agents [17]. Alkylating agents are also 
provided by N-nitrosation of amines derived from protein 
catabolism that occurs primarily in the acid environment 
of the stomach [18]. Thus, lack of MGMT function has a 
mutagenic effect that leads to G to A transition mutations. 
The human MGMT gene has a normally unmethylated 
promoter CpG island that, when hypermethylated, correlates 
with transcriptional silencing [19, 20].
A causal relationship between MGMT silencing 
and somatic mutations in KRAS and TP53 in CRC was 
initially proposed based on the association between MGMT 
hypermethylation and G > A transitions in KRAS and TP53 
[21, 22]. This view remains widely accepted [23–25], 
despite some reports with contradictory results [26–29].
SNS can be transition or transversion mutations. 
Transitions change one purine for another purine (G→A 
or A→G), or pyrimidine for another pyrimidine (C→T 
or T→C). G→A transition is the same as C→T transition 
(G→A in one strand and C→T in the other). For 
simplification we refer it as G > A transition. Most SNS 
at codons 12 (GGT) and 13 (GGC) of KRAS, activate its 
oncogenic activity. The most frequent KRAS mutations 
in CRC are G > A transitions at the second G of these 
triplets, leading to a glycine→aspartic acid substitution: 
GGT→GAT or GGC→GAC. In TP53, SNS are spread 
over the gene coding region. Of the G > A transitions, those 
occurring in CpG dinucleotides CG → TG (GC →AC in 
the reverse strand) were the most abundant in TP53 (81%).
In this study, we analyzed the association 
between KRAS and TP53 missense mutations with 
MGMT methylation in CRC with and without MSI. The 
relationship between these genetic and epigenetic somatic 
alterations was also expanded by exome sequencing 
and by in silico analysis of the publicly available data 
from The Cancer Genome Atlas (TCGA) consortium, 
(http://cancergenome.nih.gov/). As MSI CRC is very 
different from CRC without MSI (MSS) in genotype and 
phenotype, the inclusion of MSI in CRC analysis is a 
confounding factor. We then focused on the analysis of 
MSS cancers for the studies on methylation and mutation.
We also analyzed the methylation of ADAMTS14, 
a member of the ADAM/ADAMTS gene family that 
plays a role in cell migration and invasion, recently found 
altered genetically and epigenetically in carcinogenesis 
in general and CRC in particular [30–33]. We explored 
the relationship between ADAMTS14 and MGMT 
methylation in normal and tumor tissues of CRC patients 
and correlated these findings with tumor genotype and 
phenotype, including clinico-histological parameters.
RESULTS
MGMT methylation, MSI, KRAS and TP53 
mutations in CRC
In the complete series of 735 CRC 89 (12.1%) were 
classified as MSI, and 432 were analyzed for single base 
substitution (SNS) mutations in KRAS and 392 for SNS 
mutations in TP53. A subset of 261 cases was also analyzed 
for MGMT methylation. The associations between MSI, 
KRAS and TP53 mutations with CRC genotype (oncogenic 
mutations) and phenotype (clinico-pathological features) 
are summarized in supporting Figures S1–S3. MGMT 
methylation associated with African Americans ( p = 0.015) 
and there was a trend for older patients ( p < 0.1) in CRCs 
without MSI (Figure 1). No association was found between 
methylation and location, stage and grade in tumors without 
(Figure 1) or with (Figure S4) MSI. All subsequent results 
describe tumors without MSI unless otherwise specified.
MGMT methylation and type of KRAS and TP53 
mutations
In CRC, MGMT methylation associated positively 
with KRAS mutations (28% vs. 52% p = 0.0006) and 
negatively with TP53 mutations (47% vs 27%, p = 0.002) 
(Figure 2 top). MGMT methylation had no significant 
association with G > A transitions in KRAS (48% vs. 54%, 
p = 0.66) and TP53 (18% vs. 22% p = 1.0) (Figure 2a). 
There was no association between MGMT methylation and 
TP53 G > A mutations in CpG sites (Figure 2a).
Multivariate logistic regression analysis including 
all the genotypic and phenotypic characteristics of CRCs 
(Figures 1 and 2a), confirmed the statistically significant 
association of MGMT methylation with African Americans 
(OR = 3.11, p = 0.013) and KRAS mutations (OR = 2.62, 
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p = 0.013), and the negative association with TP53 
mutations (OR = 0.41, p = 0.022) (Figure S5).
To further assess our findings, we analyzed the 
matching normal and tumor samples from 36 CRCs, using 
Illumina HM450K arrays. Samples were classified into 
MGMT-methylated or demethylated based on the values 
of three probes located within the MGMT 5’ CpG island 
and enhancer region that exhibits a bimodal distribution in 
tumor samples (Materials and Methods, Figures S6 and S7). 
The concordance of the Illumina HM450K results with the 
previous MSP-based classification was 93%. We therefore 
used these three probes to explore the available public data 
from the Cancer Genome Atlas (TCGA) consortium on 
CRC (COAD plus READ databases, Figure 2b) [34]. There 
was no correlation between MGMT methylation and KRAS 
SNS in codons 12 and 13 ( p = 0.60), and non-silent TP53 
SNS were fewer in tumors with MGMT methylation ( p = 9 
× 10−4). There was no significant difference in the relative 
frequency of G > A transitions in tumors with and without 
MGMT methylation in either gene.
MGMT methylation and exome mutation 
spectrum
To study the relationship between MGMT 
hypermethylation and the overall incidence of somatic 
G > A transitions, we performed exome sequencing in 18 
CRCs and their matched normal tissues, 9 of them with 
MGMT hypermethylation. To reduce confounding factors, 
we selected only proximal colon cancers without MSI 
from Caucasian patients.
The exome sequencing data was used to estimate 
the mutation spectrum in cancers with and without MGMT 
methylation. Figure 3a shows that there was no difference 
in the frequency of G > A transitions regardless of MGMT 
methylation status. Similar result was derived in our in 
silico analysis of the TCGA consortium data. Only a weak 
positive association between MGMT methylation and G > 
A transitions in non-CpG sites was detected for both the 
entire series of cancers including the rectum ( p = 0.07) 
and proximal cancers ( p = 0.035) (Figure 3b and 3c). 
Multivariate regression analysis also revealed that MGMT 
methylation had no detectable effect in the frequency of 
SNS, including G > A transitions, in CRC without MSI 
(Figure S9). Instead, patient age showed a significant 
association with mutation for all SNS ( p = 0.009) or 
G > A transitions ( p = 1.2 × 10−4), especially those taking 
place in CpG sites ( p = 1.0 × 10−5), but not for non-G > 
A SNS ( p = 0.665) or G > A transitions in non CpG sites 
( p = 0.131) (Figure S9).
MGMT methylation and mRNA expression
MGMT methylation assessed by Illumina microarrays 
in the TCGA CRC samples showed a clear bimodal 
distribution (Figures 4c and S6). We classified samples 
into MGMT methylated or MGMT unmethylated by setting 
the ß-value threshold of 0.2, at the valley of the bimodal 
distribution of methylation. Notably, the second peak of 
this distribution was centered at a ß-value 0.5, suggestive 
of monoallelic methylation (Figure 4c and S6). Similar 
results were derived from our sample collection (Figure 
S7). In contrast, the methylation distribution of the MLH1 
gene, which is known to undergo transcriptional silencing 
by promoter methylation in CRC with MSI, showed a 
methylation peak above ß-value of 0.8, indicating biallelic 
methylation or monoallelic methylation accompanied 
by loss of the unmethylated allele (Figure 4d). MGMT 
Figure 1: MGMT methylation and genotype/phenotype of CRC without MSI. Data for MSI positive tumors are in 
Supplementary Figure S4. MGMT-hypermethylated tumors, grey; tumors without hypermethylation, white. Gender, woman vs. men; Race, 
Caucasian (Cauc.) vs. African American (Afr.Am.); Age, below median (<67 years) vs. above median (>67 years); Location, Proximal 
(proxim.) includes cecum, ascending and transversal colon vs. Distal, descending, sigmoid and rectum; Invasiveness, Dukes’ A+B vs. 
Dukes’ C+D; Differentiation, moderate to well differentiated (Mod-Well) vs. poorly differentiated (Poor). MGMT methylation was assessed 
by MSP (see Materials and Methods). p-values were calculated by univariate Fisher’s tests. In bold, statistically significant values.
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expression of the TCGA CRC samples (as assessed by 
Agilent expression microarrays), also exhibited a bimodal 
distribution, with 81.3% of the samples with an expression 
level above 0.36 (relative to the average expression of 
MGMT in 22 normal colon samples, Figure 4a), used as 
cut-off for MGMT-silencing because it coincided with the 
valley separating the two expression peaks.
MGMT methylation associated with lower expression 
(r = −0.67, p < 2.2 × 10−16, Figure 4b). However, in the 
majority of MGMT methylated cases mRNA levels were 
roughly equal to 50% of the levels in the negative cases, again 
suggesting that epigenetic silencing affected only one allele 
(Figure 4b). A minority of MGMT methylated cases exhibited 
lower expression, despite their methylation being also around 
ß = 0.5 (Figure 4b), suggesting that other mechanism, in 
addition to promoter methylation, was required for full 
MGMT transcriptional silencing in these tumors.
MGMT and ADAMTS14 methylation in normal 
mucosa of CRC
MGMT has also been found methylated in normal 
colon mucosa, having been associated with an epigenetic 
field defect for cancerization in CRC [24, 35, 36]. 
Albeit reduced compared with the tumors, there was a 
significant level of methylation in normal mucosa from 
7% (11/157) of CRC. In a parallel study we also identified 
significant methylation of ADAMTS14 in normal colon 
mucosa in 14.6% (23/157) of CRC patients (Figure 5a 
and 5b). ADAMTS14 methylation in normal mucosa 
was significantly associated with old age and was 
more frequent among African-Americans (Figure 5c). 
These associations remained statistically significant in 
multivariate logistic regression analysis (Figure 5d), with 
race being the most significant.
Figure 2: MGMT methylation and mutations in KRAS & TP53 in CRC without MSI. Symbols and codes as in Figure 1. WT; 
wild type; MUT, mutant. In the upper row, data from our tumor collection. Mutations refer to SNS at codons 12 and 13 of KRAS and in exons 
4–9 of TP53. In the lower row, TCGA COAD + READ datasets, excluding tumors classified as hypermutated (MMR defective, MSI). Only 
non-silent SNS mutations occurring in the whole coding sequence of TP53, and in codons 12 and 13 of KRAS were considered for the analysis.
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There was a significant clustering of methylation of 
MGMT and ADAMTS14 in normal tissue (Figure 6a). We 
then reclassified the 144 CRCs without MSI for which 
complete methylation information for the two genes was 
available into three groups: i) no methylation in either gene, 
ii) methylation in one or both genes in tumor, but not in 
normal tissue, and iii) methylation in normal tissue in at 
least one of these two genes. Methylation in normal tissue 
occurred preferentially in elder CRC patients ( p = 0.001) 
and African Americans ( p = 1 × 10−5) with CRC (Figure 6b).
DISCUSSION
Accumulation of mutations in KRAS and TP53 
cancer genes is critical for CRC pathogenesis. MGMT 
hypermethylation was reported to associate with KRAS 
and TP53 G > A transitions, the most frequent single 
base substitutions in both genes [21, 22]. Thus, critical 
oncogenic mutations for CRC could be explained by the 
previous MGMT epigenetic silencing. This report shows 
the absence of association between MGMT methylation 
and G > A transition mutations in KRAS and TP53 genes in 
CRC without MSI. Because this conclusion was validated 
by the massive TCGA consortium data, the results do not 
appear to be due to tumor sample variation.
Next, we performed exome sequencing to determine 
the somatic mutational spectra of 18 CRC with and 
without MGMT methylation. Again, no association was 
found between methylation and the proportion of G > A 
somatic transitions. Identical conclusion was reached 
by in silico analysis of the TCGA consortium: there was 
no association between MGMT methylation and G > A 
transition mutations in KRAS and TP53 or in the whole 
exome of 386 CRC without MSI. Therefore, epigenetic 
silencing of MGMT cannot explain the origin of the 
majority of oncogenic mutations in KRAS or TP53, 
in CRC without MSI. In support of this conclusion are 
our unpublished results with endometrial cancer (EC). 
Although KRAS mutations were identified in 34.1% MSI 
and 9.2% non-MSI EC ( p < 0.0002), none of the 204 EC 
samples exhibited MGMT methylation (data not shown).
While in MSI CRC missense mutations in KRAS 
and TP53 (and in any gene) can be accounted for by the 
strong mutator phenotype displayed by these tumors, in 
CRC without MSI the origin of these oncogenic mutations 
remains unclear [14]. While the spontaneous mutation 
rate may account for mutations in several cancer genes 
in stem cells [37, 38], it is very unlikely that the same 
gene accumulates two mutations. Thus, TP53 somatic 
biallelic mutations in cancer cannot be explained by the 
spontaneous mutation rate of normal cells [39]. This also 
applies to all tumor suppressors and mutators as the MMR 
genes themselves. Ras, however, are oncogenes and in 
principle a mono-allelic mutation may be sufficient for 
their activation. Nevertheless, the common occurrence in 
CRC is that several copies of the mutated allele coexist in 
tumors with the wild type allele, indicating that the gene 
acts in a dominant, but dose dependent manner [40–42].
As biallelic missense mutations are virtually 
absent in CRC without MSI, a plausible hypothesis is 
that the SNS common for both KRAS and TP53 occur 
spontaneously (or induced by uncharacterized mutagens) 
and that subsequent mutations in the other allele typically 
involve another type of alteration, the occurrence of 
which is enhanced over the spontaneous rate. Deletions 
and amplifications of chromosomal segments are the most 
Figure 3: MGMT methylation and somatic G > A transition mutations in CRC without MSI. (a) Data from exome sequencing 
of eighteen pairs of matching Normal-Tumor samples, 9 with (M) and without (U) MGMT hypermethylation, from our tumor collection. 
(b and c) data from proximal (b) and all (c) CRCs cancers from the TCGA, excluding hypermutated (MSI) tumors. Box plots represent the 
median percent of G > A transition mutations vs. all other single base substitutions. p-values were calculated by Student’s t-test.
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common, although not unique, mutational events that 
affect the gene dosage of KRAS and TP53 in CRC. It is 
uncertain whether these alterations are the consequence of 
a defect involved in the active generation of chromosomal 
instability, or just the result of a stepwise augmentation 
of the probability of incurring into a mitotic error during 
clonal selection. In the case of KRAS, this may be simply 
due to the increased mitotic activity presumably caused 
by the mono-allelic mutation. Whether some TP53 
monoallelic missense mutations may also work in a 
haplo-insufficiency manner increasing the chances of 
subsequent loss of heterozygosity (LOH) events is also 
a possibility, especially since the heterogeneity of these 
mutations [16]. Alternatively, the second event may be 
influenced by other independent events already present in 
the tumor cell at that stage of tumor progression.
The weak association of G > A mutations occurring 
in non-CpG sites in the cancer cell exome (Figures 3 and 
S9) shows that MGMT deficiency may indeed contribute 
to the accumulation of some of these mutations. 
Figure 4: MGMT methylation and expression in silico TCGA data of 222 CRC. (a) Distribution of MGMT expression levels 
by Agilent two-color expression microarrays, and normalized relative to the average expression level of 22 normal samples. Yellow, orange 
and red lines indicate the mean expression values of the groups defined in b. (b) Dot-plot of methylation levels vs. expression levels. By 
cutting at a relative expression of 0.36, and methylation level of 20% (ß-value = 0.2), three groups of tumors are defined: 54% of tumors 
with no MGMT methylation and average expression level similar to that of the normal tissues (yellow circles), 27.5% of tumors with 
methylation and a moderate reduction in expression (orange squares), 18.5% of tumors with reduction in expression, most but not all with 
methylation (red diamonds). (c) Distribution of the average methylation of probes cg12434587, cg12981137 and cg02941816, located in 
the promoter region of MGMT. In the normal tissues available at the TCGA, these probes never showed methylation above 20%. Of the 
222 cases analyzed, 45.05% exhibited an average methylation above 20% (dashed area) with a peak centered around 50%. Association of 
MGMT methylation with lower expression was very significant (r = −0.67, 95%CI = [−0.73,−0.59], p < 2.2 × 10−16, by Pearson’s product-
moment correlation test). (d) Methylation status of hMLH1 promoter (probe cg13846866) is shown for comparison from a comprehensive 
larger dataset of CRC from the TCGA. About 12% of the tumor samples (62/514) exhibited methylation above 20% (dashed area), with a 
peak centered around 80%.
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However, the difference in mutation frequency is very 
small, implying that many of the mutations have been 
already generated prior to the epigenetic silencing of 
the MGMT gene. In fact, the principal SNS in CRC 
are G > A transitions in CpG sites that accumulate 
in an age dependent manner (Figure S9), which is 
consistent with the hypothesis that most SNS take place 
throughout the entire life of the patient and prior to 
tumorigenesis, mainly by spontaneous deamination of 
methylated cytosines [43, 44]. Thus, mutations occurring 
after MGMT silencing may be a minority compared 
with the previous mutations accumulated during the 
life of the tumor precursor cells. The vast majority 
of these “passenger” mutations do not contribute to 
tumorigenesis, but they are exposed by the clonal 
expansion of the carrying precursor cells.
Further analysis of exome deep sequencing data 
may shed light on this issue. Non-clonal mutations (after 
transformation) would be distinguishable from clonal 
mutations by the frequency recorded in their sequence 
reads. The hypothesis can be thus tested by a comparative 
analysis in tumors with and without MGMT methylation 
of the high and low relative frequency of sequencing 
reads of G > A vs. non-G > A SNS, and between G > A 
in CpG vs. non-CpG sites. For instance, in tumors with 
MGMT methylation, the frequency of non-clonal G > A 
transitions (with low relative number of mutant vs. wild 
type sequencing reads) in non CpG sequences, would be 
higher than that from tumors without methylation.
The lack of significant correlation between 
methylation and mutation also suggests that there might 
be no significant contribution by alkylating agents in the 
large intestine to generate these mutations. However, 
even if the mutator role of MGMT hypermethylation 
appears modest, it may have a relevant prognostic 
value. Recent clinical studies showed that methylation 
of MGMT is a useful predictor of the responsiveness 
of tumors to alkylating agents in gliomas [45, 46], and 
is associated with good survival in patients treated with 
multidrug regimens [47]. It also predicts the response 
to the alkylating drug dacarbazine in metastatic CRC 
[48, 46]. In this context, the data on MGMT methylation 
and expression reveals a complex pattern of regulation 
and argues against a complete silencing in a significant 
proportion of methylated cases. This may have potential 
impact on current treatment regimens of CRC. We found 
that methylation of MGMT seems to be predominantly 
monoallelic in CRCs without MSI, with just a 50% 
reduction in transcriptional levels in the majority of the 
cases. It would be interesting to evaluate in future studies 
Figure 5: ADAMTS14 methylation and genotype/phenotype of CRC without MSI. (a) Micrographs at 200X of hematoxylin-
eosin stained representative sections of normal colonic tissue from a patient without (A) and a patient with (B and C) ADAMTS14 
hypermethylation, and tumor tissue from the latter patient (D) (b) Bisulfite sequencing profiles of the ADAMTS14 5’ region from –50 to 130 
bp, relative to the transcriptional start site (TSS) from DNA isolated from normal and tumor microdissected areas equivalent to the areas in 
micrographs A–D, and another tumor area from the same patient (E) Red and blue circles represent methylated and unmethylated CpG sites, 
respectively. (c) Associations of ADAMTS14 hypermethylation in normal mucosa of CRC patients with their phenotype/genotype. Symbols 
and codes as in Figure 1. (d) Forest plot of multivariate logistic regression analysis of the association of ADAMTS14 hypermethylation 
with race, age and location. The horizontal bars represent the 95% confidence intervals with the centered circles representing the estimated 
odds ratio, with values indicated above. p-values of the multivariate analysis are also indicated for every parameter included in the model.
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the response to these alkylating drugs in patients stratified 
in three groups (Figure 4), distinguishing between no 
silencing and mono-allelic or biallelic silencing.
In contrast with the clear asymmetries observed 
for MSI, KRAS and TP53 mutations, the only significant 
association found for MGMT methylation was with 
African-American CRC patients that tended to be 
older (Figure 1 and Figures S1–S3). In an independent 
study, we also observed a significant association of 
hypermethylation of ADAMTS14 in the normal colon 
mucosa mainly in elder African-Americans with CRC 
(Figure 5). The tendency of ADAMTS14 hypermethylation 
in normal mucosa to occur in the distal colon distinguishes 
this phenomenon from the generalized hypermethylation 
that is more prominent in tumors of the proximal colon 
[49–51]. Clustering of methylation of MGMT and 
ADAMTS14 (Figure 6a) in normal mucosa supports the 
concept of a field for cancerization in some individuals at 
high risk for CRC that involves the aberrant methylation 
of several loci, including, but not restricted to MGMT 
and ADAMTS14 [24, 36]. We do not suggest, however, 
that these genes play an active role in this field defect. 
Probably they are just markers of a more generalized 
epigenetic dysfunction that underlies an apparent high risk 
for CRC, preferentially among elderly African-Americans 
(Figure 6b).
We cannot distinguish at this point between ethnic 
or environmental causes for this association, and this 
issue remains the subject for further studies. We also do 
not know whether this phenomenon is restricted to those 
individuals already with CRC or if the alteration occurs, as 
we suspect, in pre-symptomatic individuals. The geography 
of this field defect also needs to be surveyed to discriminate 
between systemic or focalized defect. This in turn may 
have practical consequences for diagnosis of the predictive 
lesions. Although their detection may be a challenging task, 
epigenetic alterations can be detected in liquid biopsies. In 
conclusion, our findings provide mechanistic clues for the 
ethnic disparities known to affect colon cancer [52], and a 
rationale for novel CRC predictive tests.
Figure 6: ADAMST14 and MGMT methylation and genotype/phenotype of CRC without MSI. (a) Clustering of MGMT 
and ADAMTS14 hypermethylation in the normal mucosa (left) and tumor tissue (right) of CRC patients. p-values were calculated by 
Fisher’s exact test. (b) Patients were divided into three groups according to the methylation status of ADAMTS14 and MGMT: without 
methylation in either gene (white), with methylation in one or both genes in the tumor sample but not in the non-tumoral mucosa (light 
grey), or with methylation of at least one of these genes in the non-tumoral mucosa (dark grey). Symbols and codes as in Figure 1. p-values 
were calculated by χ2 test.
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PATIENTS AND METHODS
Study participants and samples
Unselected primary CRC and corresponding non-
tumoral tissues were obtained through the Cooperative 
Human Tissue Network (CHTN) from 751 patients 
who underwent curative surgery in various hospitals of 
Philadelphia, Tennessee, Ohio and Alabama between 
1985 and 2004. Only patients with adenocarcinomas 
were included in the study. Clinical information 
included age at diagnosis, gender, race, tumor location, 
and surgical stage; and pathology data included grade 
of differentiation. Tumor staging was based on Duke’s 
classification. Sanford-Burnham Institutional Review 
Board approval was obtained for this work. We also 
retrospectively studied 204 consecutive patients with 
EC (FIGO stage I-III), diagnosed and treated at the 
Department of Obstetrics and Gynecology of the Gran 
Canaria’s Hospital Universitario Materno Infantil (Canary 
Islands, Spain) between 1990 and 1999. The ethics 
committees from Gran Canaria’s Hospital Universitario 
Materno Infantil approved the research protocol, 
which was in compliance with national legislation and 
performed according to the ethical guidelines of the 
Declaration of Helsinki [53]. After surgical resection, 
samples were rapidly frozen in liquid nitrogen and stored 
at −80ºC until further use. DNA was isolated by standard 
procedures involving mechanical disruption of tissue, 
SDS lysis and proteinase K digestion, phenol-chloroform 
extraction, and ethanol precipitation [54].
MSI analysis, KRAS and TP53 mutation 
detection
MSI was determined in 751 CRC as previously 
described. [55] Codons 12/13 of the KRAS oncogene 
in 432 CRC, and exons 4 to 8 of the TP53 suppressor 
gene in 392 CRC were analyzed by single stranded 
conformation polymorphism (SSCP) and DNA 
sequencing. PCR primers and conditions for the 
amplification and analysis of these genes are detailed in 
supporting materials SM1.
Methylation analysis of MGMT and  
ADAMTS14
The methylation status of MGMT was determined 
in 273 CRC samples by methylation-specific single 
PCR (MSP) [56] of a specific sequence region where 
methylation invariably correlates with lack of MGMT 
expression [19, 20]. PCR primers and conditions are 
described in supporting materials SM2. The promoter 
region of ADAMTS14 was analyzed by bisulfite 
sequencing and combined bisulfite and restriction analysis 
(COBRA) in 158 CRC patients (supporting materials 
SM3) [57, 58].
Exome sequencing
We sequenced 36 exomes corresponding to tumor 
tissue and corresponding normal mucosa from 18 patients 
with proximal colon cancer (9 with and 9 without 
MGMT methylation), using Illumina TruSeq Enrichment 
protocol and HiScan-SQ platform. Somatic mutations 
were determined by comparing the tumor and normal 
exome from the same individual. Detailed information 
about the library preparation, sequencing protocol and 
bioinformatic tools is provided in supporting information 
SM4. After exome sequencing, over 100 Single 
nucleotide variants (SNVs) and somatic mutations were 
manually selected for validation by PCR and sequencing 
(supporting materials SM5).
In silico analysis of TCGA data
We combined the data from the COAD (colon 
adenocarcinoma) and READ (rectum adenocarcinoma) 
databases from the TCGA (https://tcga-data.nci.nih.
gov/) [34]. In total, we obtained clinical information 
from 592 patients, methylation data from 583 primary 
CRCs, and exome mutational data from 386 CRCs 
(supporting dataset S1). MGMT methylation status 
was determined by Illumina HM27/HM450 probes 
cg12434587, cg12981137 and cg02941816, that 
interrogate three CpG sites located –239 bp, 128 
bp and 248 bp from the MGMT transcriptional start 
site, respectively, within regions that associate with 
transcription of MGMT. [20] A detailed explanation 
of the TCGA datasets we employed in this work and 
the classification criteria for MSI and MGMT status are 
provided in supporting materials SM6.
Statistical analysis
Statistical analyses were performed using R 
environment [59]. Associations in categorical data 
were analyzed by two-sided Fisher’s exact tests (for 
2 × 2 contingency tables) or Chi-squared test with Yates’ 
correction (for larger contingency tables). Multivariate 
analyses were performed by logistic regression, with 
stepwise reduction of non-significant factors and 
interactions. Forest plots represent the odds ratios (OR) 
and the 95% confidence intervals for each parameter 
included in the model. In box plots, the boxes represent the 
interquantile range (IQR) with a horizontal bar indicating 
the median. Dispersion bars indicate the highest and 
lowest datum within 1.5 × IQR of the lower quartile and 
1.5 × IQR of the highest quartile. Statistical significance 
threshold was set at p ≤ 0.05.
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